{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:07:52Z","timestamp":1789538872015,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jval.2022.11.018","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T03:42:45Z","timestamp":1670470965000},"page":"487-497","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cost-Effectiveness of Tepotinib Versus Capmatinib for the Treatment of Adult Patients With Metastatic Non\u2013Small Cell Lung Cancer Harboring Mesenchymal\u2013Epithelial Transition Exon 14 Skipping"],"prefix":"10.1016","volume":"26","author":[{"given":"Mo","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Vioix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rameet","family":"Sachdev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Stargardter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Tosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris M.","family":"Pfeiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul K.","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jval.2022.11.018_bib2","first-page":"122","article-title":"Treatment of advanced non small cell lung cancer","volume":"3","author":"Bareschino","year":"2011","journal-title":"J\u00a0Thorac Dis"},{"issue":"1","key":"10.1016\/j.jval.2022.11.018_bib3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jtho.2016.10.014","article-title":"Targeting MET in lung cancer: will expectations finally be MET?","volume":"12","author":"Drilon","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"issue":"6","key":"10.1016\/j.jval.2022.11.018_bib4","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1158\/2159-8290.CD-16-1337","article-title":"Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies","volume":"7","author":"Jordan","year":"2017","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.jval.2022.11.018_bib5","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrc3775","article-title":"Non-small-cell lung cancers: a heterogeneous set of diseases","volume":"14","author":"Chen","year":"2014","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"10.1016\/j.jval.2022.11.018_bib6","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jtho.2016.06.004","article-title":"Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations","volume":"11","author":"Schrock","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"issue":"10026","key":"10.1016\/j.jval.2022.11.018_bib7","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/S0140-6736(15)01125-3","article-title":"Large-scale screening for somatic mutations in lung cancer","volume":"387","author":"Rosell","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jval.2022.11.018_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-01025-7","article-title":"Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer","volume":"14","author":"Drusbosky","year":"2021","journal-title":"J\u00a0Hematol Oncol"},{"issue":"10","key":"10.1016\/j.jval.2022.11.018_bib9","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.jval.2022.11.018_bib10","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET exon 14\u2013mutated or MET-amplified non\u2013small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.jval.2022.11.018_bib11","first-page":"131","article-title":"Budget impact of capmatinib for adults with metastatic non-small cell lung cancer harboring a MET exon 14 skipping mutation in the United States","volume":"24","author":"Cai","year":"2021","journal-title":"J\u00a0Med Econ"},{"issue":"1","key":"10.1016\/j.jval.2022.11.018_bib12","first-page":"816","article-title":"Budget impact of tepotinib in the treatment of adult patients with metastatic non-small cell lung cancer harboring METex14 skipping alterations in the United States","volume":"24","author":"Stargardter","year":"2021","journal-title":"J\u00a0Med Econ"},{"issue":"6","key":"10.1016\/j.jval.2022.11.018_bib13","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1158\/1078-0432.CCR-21-2733","article-title":"Tepotinib efficacy and safety in patients with MET exon 14 skipping NSCLC: outcomes in patient subgroups from the VISION study with relevance for clinical practice","volume":"28","author":"Le","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"95","key":"10.1016\/j.jval.2022.11.018_bib14","article-title":"Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: a review of preclinical and clinical studies","volume":"95","author":"Wu","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10.1016\/j.jval.2022.11.018_bib15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s40291-021-00568-w","article-title":"MET-targeted therapies and clinical outcomes: a systematic literature review","volume":"26","author":"Dong","year":"2022","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.jval.2022.11.018_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1758835921992976","article-title":"Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer","volume":"13","author":"Hong","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"14","key":"10.1016\/j.jval.2022.11.018_bib17","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s40265-021-01584-0","article-title":"First approval","volume":"81","author":"Savolitinib","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.jval.2022.11.018_bib18","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines \u00ae) for Guideline Name V.3.2022. \u00a9 National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed March 16, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"issue":"10","key":"10.1016\/j.jval.2022.11.018_bib19","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2022.11.018_bib20","unstructured":"The healthcare business of Merck KGaA, Darmstadt, Germany. Indirect Treatment Comparison (ITC) in Advanced NSCLC with METex14 mutation skipping (Tissue BIOPSY): VISION data. 2021 data cut (Cohort A). 2021."},{"key":"10.1016\/j.jval.2022.11.018_bib25","unstructured":"Tepotinib phase II in NSCLC harboring MET alterations. EMD Serono. Clinical Study Report. 2020."},{"issue":"1","key":"10.1016\/j.jval.2022.11.018_bib27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/21556660.2018.1445092","article-title":"Treatment patterns, clinical and economic outcomes of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer receiving ceritinib: a retrospective observational claims analysis","volume":"7","author":"Dalal","year":"2018","journal-title":"J\u00a0Drug Assess"},{"issue":"4","key":"10.1016\/j.jval.2022.11.018_bib28","first-page":"31","article-title":"Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR exon 19 deletion mutations","volume":"2","author":"Graham","year":"2016","journal-title":"J\u00a0Clin Pathw"},{"key":"10.1016\/j.jval.2022.11.018_bib29","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.lungcan.2018.08.018","article-title":"Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer","volume":"124","author":"Georgieva","year":"2018","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.jval.2022.11.018_bib30","doi-asserted-by":"crossref","first-page":"75s","DOI":"10.1200\/JOP.2011.000469","article-title":"Health care costs for patients with cancer at the end of life","volume":"8","author":"Chastek","year":"2012","journal-title":"J\u00a0Oncol Pract"},{"issue":"suppl 5","key":"10.1016\/j.jval.2022.11.018_bib31","doi-asserted-by":"crossref","first-page":"S985","DOI":"10.1016\/j.annonc.2021.08.1858","article-title":"1255P health utility with tepotinib in patients (pts) with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC)","volume":"32","author":"Reinmuth","year":"2021","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.jval.2022.11.018_bib34","first-page":"3079","article-title":"A\u00a0phase II study of the combination of docetaxel and bevacizumab for previously treated non-small cell lung cancer","volume":"47","author":"Shimizu","year":"2019","journal-title":"J\u00a0Int Med Res"},{"issue":"20","key":"10.1016\/j.jval.2022.11.018_bib35","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1200\/JCO.2008.20.8181","article-title":"Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer","volume":"27","author":"Patel","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jval.2022.11.018_bib37","author":"Latimer"},{"issue":"6","key":"10.1016\/j.jval.2022.11.018_bib40","first-page":"577","article-title":"Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States","volume":"21","author":"Zhou","year":"2018","journal-title":"J\u00a0Med Econ"},{"issue":"1","key":"10.1016\/j.jval.2022.11.018_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0226196","article-title":"Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France","volume":"15","author":"Sivignon","year":"2020","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jval.2022.11.018_bib42","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40273-018-0625-6","article-title":"Cost effectiveness of alectinib vs. crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer","volume":"36","author":"Carlson","year":"2018","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"10.1016\/j.jval.2022.11.018_bib47","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jval.2012.06.012","article-title":"Modeling good research practices - overview: a report of the ISPOR-SMDM modeling good research practices task force-1","volume":"15","author":"Caro","year":"2012","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.jval.2022.11.018_bib48","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.37765\/ajmc.2021.88726","article-title":"Cost-effectiveness of nivolumab in patients with NSCLC in the United States","volume":"27","author":"Chaudhary","year":"2021","journal-title":"Am J Manag Care"},{"issue":"2","key":"10.1016\/j.jval.2022.11.018_bib50","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jval.2021.08.009","article-title":"Cost-effectiveness of Cemiplimab versus standard of care in the United States for first-line treatment of advanced non-small cell lung cancer with programmed death-ligand 1 expression \u226550","volume":"25","author":"Kuznik","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2022.11.018_bib51","unstructured":"Fusion: Flatiron unmet need study in clinical outcomes among METex14 skipping non-small cell lung cancer. EMD Serono. 2020."},{"issue":"7","key":"10.1016\/j.jval.2022.11.018_bib52","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1007\/s12325-022-02163-9","article-title":"Matching-adjusted indirect comparison (MAIC) of tepotinib with other MET inhibitors for the treatment of advanced NSCLC with MET exon 14 skipping mutations","volume":"39","author":"Paik","year":"2022","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.jval.2022.11.018_bib53","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/0272989X17725740","article-title":"Methods for population-adjusted indirect comparisons in health technology appraisal","volume":"38","author":"Phillippo","year":"2018","journal-title":"Med Decis Making"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301522047507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301522047507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:31:16Z","timestamp":1761096676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301522047507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1098301522047507"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2022.11.018","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Tepotinib Versus Capmatinib for the Treatment of Adult Patients With Metastatic Non\u2013Small Cell Lung Cancer Harboring Mesenchymal\u2013Epithelial Transition Exon 14 Skipping","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2022.11.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}